Beijing Elite Technology Co., Ltd. specializes in the manufacturing of industrial robots, focusing on advanced automation solutions. The company has developed a seven-axis collaborative robot that employs deep neural network technology to effectively identify and capture irregularly shaped objects. By integrating 2D and 3D data, this system enhances the accuracy of depth vision sensors, resulting in improved capture success rates and increased versatility in handling various items. Elite Technology's robotic systems are applicable across multiple sectors, including 3C (computers, communications, and consumer electronics), logistics, retail, and catering, showcasing their potential to streamline operations in diverse industrial environments.
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.
Innoforce Pharmaceuticals Co., Ltd, a biopharmaceutical company, engages in the development and commercialization of biomedicines and therapies. It develops cell and gene therapies, medicines, and antibodies. It also operates biologic process development laboratories. The company was founded in 2018 and is based in Hangzhou, China.
Ablaze Pharma is a clinical stage bio-pharmaceutical company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients.
Zhimeng Biopharma, Inc. is a pharmaceutical company based in Shanghai, China, established in 2017. The company focuses on developing innovative treatments for chronic hepatitis B (CHB) and related liver diseases, with a pipeline that includes a HBV capsid inhibitor, HBsAg inhibitor, and various immunomodulators. In addition to its work on hepatitis B, Zhimeng is also advancing small molecule drugs aimed at treating neurological disorders, including epilepsy, pain, and strokes. The company's research targets multiple stages of the hepatitis B virus, with the goal of enhancing treatment options available to healthcare professionals and improving patient outcomes.
Boan Biotech is a biopharmaceutical company developing therapeutic antibodies with a focus on key therapeutic areas including oncology, metabolism, autoimmunity, and ophthalmology.
Zhuanzhuan is an online marketplace on which users can buy and sell secondhand goods. Moreover, Zhuanzhuan operates as a goods trading unit of China's largest online marketplace, 58.com Launched in November 2015, the company is headquartered in China.
OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue.
OncoNano Medicine is a UTSW spinoff company based in Dallas, Texas.
Stemirna Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2016. The company specializes in developing mRNA technology-based drug solutions, with a focus on personalized cancer vaccines, mRNA vaccines for infectious diseases, and treatments for genetic and protein defect diseases. Stemirna has established a comprehensive mRNA drug platform that includes a GMP production center and a tumor neoantigen library, along with a clinical cooperation platform for mRNA drug development. With more than a dozen independently-developed projects, Stemirna aims to harness the potential of RNA science to provide safe and effective therapeutic options for patients suffering from various medical conditions.
Boan Biotech is a biopharmaceutical company developing therapeutic antibodies with a focus on key therapeutic areas including oncology, metabolism, autoimmunity, and ophthalmology.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Impelex Data Transfer Co., Ltd., founded in 2013 and based in Taichung, Taiwan, specializes in system integration services aimed at enhancing smart manufacturing solutions for the metal processing and hand tool production industries. The company focuses on forming strategic alliances to deliver innovative and efficient manufacturing technologies, addressing the evolving needs of these sectors.
Kaiyi Technology provides vehicles with assisted driving safety algorithms through image recognition, machine learning, and artificial intelligence. Focusing on the front-loading ADAS algorithm, it also designed an algorithm model for the aftermarket, providing the ADAS SDK for in-vehicle intelligent hardware, and implementing accurate ADAS functions on various hardware platforms, which will make greater contributions to the field of autonomous driving in the future.
Alphamab Oncology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of biologics for cancer treatment. The company has established a diverse product pipeline that includes several innovative therapeutics, such as KN046, a bispecific monoclonal antibody targeting PD-L1 and CTLA-4, currently in Phase II trials, and KN026, a next-generation anti-HER2 bispecific antibody also in Phase II. Additionally, the pipeline features KN019, a CTLA-4-based immunosuppressant fusion protein with potential applications in autoimmune diseases and oncology-related immune disorders, and KN035, an injectable PD-L1 inhibitor undergoing pivotal Phase II and III trials for various cancers. Founded in 2008, Alphamab Oncology utilizes proprietary platforms in bispecifics and protein engineering to address unmet medical needs globally.
Mojo Vision is a company based in Saratoga, California, that specializes in augmented reality products and platforms. Founded in 2015, it has developed a smart contact lens featuring a built-in display that provides timely information without disrupting the user's focus. This innovative technology enables users to receive immediate and relevant information, facilitating hands-free communication and interaction. By minimizing the distractions associated with traditional mobile devices, Mojo Vision aims to enhance connectivity and accessibility for users in various environments.
InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company is advancing a pipeline of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Notably, it is developing D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor, and is exploring combinations of its drugs with other immuno-oncology therapies, such as PD-1 antibodies, for various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with prior experience at major pharmaceutical companies like Merck and Schering-Plough, InventisBio aims to leverage their expertise in oncology and metabolic diseases to bring effective treatments to market.
AutoAI Technology Co., Ltd. develops a platform, which provides navigation technologies to connected vehicles. It offers holistic solutions based on data and cloud portal to provide Internet services into the car. The company also offers on-board components, such as a telematics box, a vehicle-optimized version of the android operating system or cloud-based technologies for data acquisition, storage, and analysis; and entertainment, weather and traffic information, parking, fueling, and insurance services for drivers. The company was founded in 2018 and is based in Beijing, China. AutoAI Technology Co., Ltd. operates as a subsidiary of NavInfo Co., Ltd.
Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.
Emotibot Technologies specializes in designing and developing artificial intelligence systems with a focus on emotional intelligence. Founded in 2015 and based in Shanghai, the company creates AI bots capable of reading, listening, and understanding emotions through multi-modal recognition and machine learning. Its product offerings include various bots such as Personal Bot, Fin Bot, and Service Bot, as well as emotion recognition tools like Emoti-Voice and Fatigue Detection. These systems are applicable across multiple sectors, including e-commerce, finance, and smart devices, and can facilitate humanized conversations and vision understanding in environments such as mobile devices, homes, and automobiles.
Alphamab Oncology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of biologics for cancer treatment. The company has established a diverse product pipeline that includes several innovative therapeutics, such as KN046, a bispecific monoclonal antibody targeting PD-L1 and CTLA-4, currently in Phase II trials, and KN026, a next-generation anti-HER2 bispecific antibody also in Phase II. Additionally, the pipeline features KN019, a CTLA-4-based immunosuppressant fusion protein with potential applications in autoimmune diseases and oncology-related immune disorders, and KN035, an injectable PD-L1 inhibitor undergoing pivotal Phase II and III trials for various cancers. Founded in 2008, Alphamab Oncology utilizes proprietary platforms in bispecifics and protein engineering to address unmet medical needs globally.
Xiaozhu.com (小猪短租网) is a Chinese booking website for daily rental and short-term rooms. It aims to provide a guaranteed platform for online communication and transactions for landlords and tenants. Also, a green platform ecosystem is established by mechanisms such as property and personal safety guarantee schemes as well as identification. This will effectively take full advantages and maximize the value of landlords' idle resources through sharing. Meanwhile, it enhances the social relationship and interaction between landlords and tenants and provides tenants with more humanized accommodation experience which is different from traditional hotels. Currently, the company has had branches in 13 cities all over the country and its house sources cover more than 130 domestic cities.
Advantech Technologies Japan focuses on high-mix and small volume tailor-made embedded design-in services. The company was formerly known as OMRON Nohgata, a subsidiary of Omron Corporation, which was acquired by Advantech in 2018. ATJ is based in Nogata, Fukuoka, Japan.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Ideanomics is a multinational company dedicated to accelerating the commercial adoption of electric vehicles and advancing financial technology solutions. Its Mobile Energy Global (MEG) division supports commercial fleet operators by providing a range of services, including vehicle procurement, finance, leasing, and energy management, all integrated under a unique sales to financing to charging model. The Ideanomics Mobility unit specializes in electric vehicles, encompassing various applications such as delivery trucks, vans, and two-wheelers, while Ideanomics Energy focuses on charging infrastructure and energy-related services. Additionally, Ideanomics Capital offers financing solutions to support the company's mobility and energy initiatives. Headquartered in New York, the company operates internationally with offices in China and activities spanning multiple countries, emphasizing its commitment to technological innovation and efficiency in the evolving transportation and financial sectors.
Zhihu (知乎) is a Chinese socialized website for questions and answers. It differs from traditional online question and answer forums by enabling users to obtain information through questions that provoke the opinions and views from answerers as individuals. The number of registered users on Zhihu has surpassed 300,000 by the end of January 2012. Zhihu was founded in 2011.
Sinovac Biotech Ltd. is a biopharmaceutical company based in Beijing, China, specializing in the research, development, manufacture, and commercialization of vaccines for human infectious diseases. Its product portfolio includes vaccines for hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza, mumps, and enterovirus 71, among others. Key marketed products include Healive, a hepatitis A vaccine, Bilive, a combined hepatitis A and B vaccine, and Panflu.1, which was the first H1N1 vaccine approved globally. Sinovac also plays a significant role in government stockpiling programs for vaccines in China. The company is actively developing new vaccines, including those for pneumococcal disease and rubella, with various clinical trials underway. Sinovac collaborates with notable institutions such as GlaxoSmithKline and Tianjin CanSino Biotechnology to enhance its vaccine development efforts. Established in 1999, Sinovac primarily sells its products in China while also exporting selected vaccines to countries like Mongolia, Nepal, and the Philippines.
Nanos Medical is engaged in the research and development, manufacturing and sales of disposable medical devices. The company's current core products are concentrated in the cardiovascular and ENT fields.
Qutoutiao Inc. operates a mobile platform focused on the distribution and consumption of light entertainment content in China. Founded in 2016 and headquartered in Shanghai, the company is known for its flagship application, Qutoutiao, which aggregates articles and short videos, delivering customized feeds to users through an AI-driven recommendation engine. This platform enhances user engagement by optimizing content based on individual profiles and social interactions. Additionally, Qutoutiao offers Midu Novels and Midu Lite, mobile literature applications that provide users with free access to literature supported by advertising revenue. The company employs a gamified loyalty system that encourages user participation by allowing registered users to earn points for engaging with content and referring new users, ultimately aiming to increase user retention and satisfaction. As the second-largest mobile content aggregator in China, Qutoutiao plays a significant role in the evolving landscape of digital content consumption.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
KBP Biosciences Co., Ltd. is a biotechnology company based in Jinan, China, with additional offices in Beijing, Japan, and the United States. Founded in 2002, the company focuses on the research and development of drugs targeting infectious and metabolic diseases. Its comprehensive research platform employs structure-based drug design, in vitro and cell-based biological screening, and pharmacodynamic and pharmacokinetic evaluation, alongside ADME profiling and pre-clinical animal pharmacology and toxicity analysis. KBP Biosciences also offers services related to the transfer of new drugs, licensing, and intellectual property protection, which includes patent scope analysis, novelty analysis, and patent writing and filing. The organization is committed to delivering innovative therapies to address unmet medical needs.
DTRM Biopharma
Series A in 2018
Biopharma company.
Petuum, Inc. is a technology company based in Pittsburgh, Pennsylvania, that focuses on making advanced machine learning and artificial intelligence accessible to a wide range of businesses. Founded in 2014, Petuum offers a comprehensive machine learning infrastructure platform that includes the Petuum Operating System (PetuumOS), a tool that facilitates the development, deployment, and management of machine learning and deep learning applications across various hardware environments. The company's solutions, such as Petuum Poseidon for deep learning computing and PetuumMed for healthcare applications, enable users to create and manage AI applications efficiently and cost-effectively. By providing a flexible platform that supports any programming language and type of data, Petuum aims to lower the barriers to AI adoption, enhance productivity, and improve service delivery across multiple industries.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Petuum, Inc. is a technology company based in Pittsburgh, Pennsylvania, that focuses on making advanced machine learning and artificial intelligence accessible to a wide range of businesses. Founded in 2014, Petuum offers a comprehensive machine learning infrastructure platform that includes the Petuum Operating System (PetuumOS), a tool that facilitates the development, deployment, and management of machine learning and deep learning applications across various hardware environments. The company's solutions, such as Petuum Poseidon for deep learning computing and PetuumMed for healthcare applications, enable users to create and manage AI applications efficiently and cost-effectively. By providing a flexible platform that supports any programming language and type of data, Petuum aims to lower the barriers to AI adoption, enhance productivity, and improve service delivery across multiple industries.
Rokid Corporation is an artificial intelligence and robotics company founded in 2014, with its headquarters in Hangzhou, China, and research centers in Beijing and San Francisco. The company specializes in developing smart home devices, including Pebble and Alien, which utilize advanced AI and deep learning to facilitate voice and visual interactions. Rokid's products offer various functionalities, such as access to weather updates, smart home automation, music, and basic chat, enhancing user experience through multi-dimensional interaction. The company's focus on speech recognition, natural language processing, and image recognition allows its devices to cater to specific consumer needs. Additionally, Rokid has received recognition for its innovation, winning CES innovation awards consecutively in 2016 and 2017. This commitment to superior industrial design and user experience positions Rokid as a leader in the fields of robotics and AI technology.
Tongdun Technology is a Chinese fintech start-up specializing in risk control services.
The company develops online software solutions for anti-theft and fraud management applications in financial, insurance, payment, online shopping, and social networking companies. The company was founded in 2013 and is based in Hangzhou, China.
Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.
Advantech B+B SmartWorx Inc. designs, builds, and delivers connectivity and communication solutions for a range of applications. It offers Wzzard design and development kits, industrial Wzzard intelligent edge nodes, commercial Wzzard intelligent edge nodes, and spectra 4G cellular Wi-Fi routers; Ethernet serial device servers, cables and other supporting accessories, and Modbus gateways and protocol converters; and Ethernet switches, extenders, and routers.
GPEG Ltd. is a manufacturer and designer of specialized display solutions, primarily catering to the gaming industry. The company develops a range of products, including custom LCDs, Kickstart LCD modules, custom touchscreens, and monitors. Additionally, GPEG Ltd. produces alphanumeric LCD modules, monochrome graphics, and TFT modules, emphasizing intelligent displays tailored to specific applications. Their focus on creating bespoke display solutions positions them as a unique provider in the market.
Innocore Gaming specializes in designing and manufacturing of hardware and software to the gaming industry. The company produces computer boards and other accessories for gaming applications.
DLoG GmbH develops robust and mobile industry computer solutions for applications in intra logistics, on large machines and in industrial manufacturing. Their industry computers prove themselves everywhere where visualizations are required under tough environmental or surrounding conditions.